Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status.
Yoshimitsu ShimomuraMasahiko HaraShigeki HirabayashiTadakazu KondoShohei MizunoNaoyuki UchidaJunichi MukaeToshiro KawakitaTakahiro FukudaYoshinobu KandaShuichi OtaYukiyasu OzawaTetsuya EtoYumiko MaruyamaMasatsugu TanakaNobuaki NakanoTakafumi KimuraTatsuo IchinoheYoshiko AtsutaMasamitsu YanadaPublished in: Bone marrow transplantation (2021)